25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARWR (Arrowhead Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Arrowhead Pharmaceuticals Inc together

I guess you are interested in Arrowhead Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Arrowhead Pharmaceuticals Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Arrowhead Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Arrowhead Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arrowhead Pharmaceuticals Inc

I send you an email if I find something interesting about Arrowhead Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Arrowhead Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Arrowhead Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.95
Expected worth in 1 year
$6.32
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$1.37
Return On Investment
8.1%

For what price can you sell your share?

Current Price per Share
$16.79
Expected price per share
$14.92 - $17.49
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arrowhead Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$16.79
Intrinsic Value Per Share
$32.92 - $156.25
Total Value Per Share
$37.87 - $161.20

2.2. Growth of Arrowhead Pharmaceuticals Inc (5 min.)




Is Arrowhead Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$684.2m$334.5m-$16.9m-5.3%

How much money is Arrowhead Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$36.6m-$117.6m$81m221.2%
Net Profit Margin-0.4%-1,268.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Arrowhead Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#96 / 881

Most Revenue
#58 / 881

Most Profit
#737 / 881

Most Efficient
#392 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arrowhead Pharmaceuticals Inc?

Welcome investor! Arrowhead Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Arrowhead Pharmaceuticals Inc.

First you should know what it really means to hold a share of Arrowhead Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Arrowhead Pharmaceuticals Inc is $16.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arrowhead Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arrowhead Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.95. Based on the TTM, the Book Value Change Per Share is $0.34 per quarter. Based on the YOY, the Book Value Change Per Share is $0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arrowhead Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.6615.9%-0.27-1.6%-0.85-5.1%-0.46-2.7%-0.36-2.1%-0.21-1.2%
Usd Book Value Change Per Share4.5527.1%0.342.0%0.050.3%0.140.8%0.070.4%0.100.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.5527.1%0.342.0%0.050.3%0.140.8%0.070.4%0.100.6%
Usd Price Per Share12.74-19.23-30.43-27.74-40.98-27.17-
Price to Earnings Ratio1.20--2.93--9.06--7.88--28.91--36.94-
Price-to-Total Gains Ratio2.80--14.37--30.84-8.25--523.42--288.37-
Price to Book Ratio2.57-18.37-14.53-17.21-18.07-14.37-
Price-to-Total Gains Ratio2.80--14.37--30.84-8.25--523.42--288.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.79
Number of shares59
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.340.07
Usd Total Gains Per Share0.340.07
Gains per Quarter (59 shares)20.174.07
Gains per Year (59 shares)80.6716.29
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1081710166
2016115203322
3024223304938
4032331406554
5040339508170
6048447609886
705655570114102
806456380130118
907267190147134
1008078000163150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%14.094.01.012.8%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%14.026.00.035.0%38.069.02.034.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0109.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%14.026.00.035.0%38.069.02.034.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arrowhead Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.5490.342+1231%0.055+8193%0.140+3150%0.069+6489%0.098+4553%
Book Value Per Share--4.9552.300+115%2.423+105%2.444+103%2.743+81%1.939+155%
Current Ratio--4.2925.443-21%5.679-24%5.592-23%5.480-22%5.288-19%
Debt To Asset Ratio--0.5650.740-24%0.587-4%0.630-10%0.495+14%0.363+56%
Debt To Equity Ratio--1.3016.569-80%1.667-22%3.446-62%2.255-42%1.290+1%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1055830000.0002283937500.000-54%4151264250.000-75%3688951166.667-71%5650169626.950-81%3793972834.400-72%
Eps--2.664-0.265+110%-0.852+132%-0.461+117%-0.357+113%-0.208+108%
Ev To Ebitda Ratio--0.651-3.070+571%-9.653+1582%-8.520+1408%-29.456+4624%-33.083+5181%
Ev To Sales Ratio--0.4861.339-64%138.675-100%57.807-99%70.238-99%872.866-100%
Free Cash Flow Per Share--3.2930.017+18856%-0.851+126%-0.491+115%-0.262+108%-0.144+104%
Free Cash Flow To Equity Per Share--3.9621.018+289%-0.067+102%0.292+1256%0.215+1746%0.175+2161%
Gross Profit Margin--1.0001.0010%1.0010%1.0010%1.0000%1.0000%
Intrinsic Value_10Y_max--156.248----------
Intrinsic Value_10Y_min--32.916----------
Intrinsic Value_1Y_max--1.776----------
Intrinsic Value_1Y_min---1.077----------
Intrinsic Value_3Y_max--15.914----------
Intrinsic Value_3Y_min--0.534----------
Intrinsic Value_5Y_max--42.808----------
Intrinsic Value_5Y_min--6.266----------
Market Cap2318699000.000+24%1759394000.0002654972500.000-34%4202728250.000-58%3830548750.000-54%5659890400.000-69%3752487725.000-53%
Net Profit Margin--0.678-0.004+101%-12.684+1971%-4.667+789%-3.447+609%-73.370+10924%
Operating Margin--0.7210.027+2594%-12.549+1841%-4.606+739%-3.441+577%-75.580+10584%
Operating Ratio--0.2980.244+22%14.080-98%5.564-95%4.422-93%144.322-100%
Pb Ratio3.389+24%2.57118.365-86%14.528-82%17.215-85%18.066-86%14.371-82%
Pe Ratio1.576+24%1.196-2.932+345%-9.062+858%-7.884+759%-28.909+2518%-36.937+3189%
Price Per Share16.790+24%12.74019.225-34%30.433-58%27.738-54%40.984-69%27.172-53%
Price To Free Cash Flow Ratio1.275+24%0.967-3.576+470%-10.492+1185%-9.179+1049%-23.994+2581%-17.035+1861%
Price To Total Gains Ratio3.691+24%2.801-14.366+613%-30.838+1201%8.253-66%-523.417+18787%-288.374+10396%
Quick Ratio--25.41814.296+78%9.520+167%11.031+130%9.687+162%7.992+218%
Return On Assets--0.234-0.070+130%-0.154+166%-0.092+139%-0.073+131%-0.079+134%
Return On Equity--0.538-1.047+295%-0.443+182%-0.578+207%-0.373+169%-0.238+144%
Total Gains Per Share--4.5490.342+1231%0.055+8193%0.140+3150%0.069+6489%0.098+4553%
Usd Book Value--684225000.000317584250.000+115%334566500.000+105%337518166.667+103%378757066.850+81%267826479.975+155%
Usd Book Value Change Per Share--4.5490.342+1231%0.055+8193%0.140+3150%0.069+6489%0.098+4553%
Usd Book Value Per Share--4.9552.300+115%2.423+105%2.444+103%2.743+81%1.939+155%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1055830000.0002283937500.000-54%4151264250.000-75%3688951166.667-71%5650169626.950-81%3793972834.400-72%
Usd Eps--2.664-0.265+110%-0.852+132%-0.461+117%-0.357+113%-0.208+108%
Usd Free Cash Flow--454756000.0002399000.000+18856%-117540750.000+126%-67811666.667+115%-36176489.350+108%-19914643.150+104%
Usd Free Cash Flow Per Share--3.2930.017+18856%-0.851+126%-0.491+115%-0.262+108%-0.144+104%
Usd Free Cash Flow To Equity Per Share--3.9621.018+289%-0.067+102%0.292+1256%0.215+1746%0.175+2161%
Usd Market Cap2318699000.000+24%1759394000.0002654972500.000-34%4202728250.000-58%3830548750.000-54%5659890400.000-69%3752487725.000-53%
Usd Price Per Share16.790+24%12.74019.225-34%30.433-58%27.738-54%40.984-69%27.172-53%
Usd Profit--367863000.000-36637750.000+110%-117697250.000+132%-63966750.000+117%-49449946.400+113%-28869158.475+108%
Usd Revenue--542709000.000198177250.000+174%8868250.000+6020%91748500.000+492%72676131.650+647%43079437.650+1160%
Usd Total Gains Per Share--4.5490.342+1231%0.055+8193%0.140+3150%0.069+6489%0.098+4553%
 EOD+4 -4MRQTTM+27 -11YOY+28 -103Y+27 -115Y+27 -1110Y+26 -12

3.3 Fundamental Score

Let's check the fundamental score of Arrowhead Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.576
Price to Book Ratio (EOD)Between0-13.389
Net Profit Margin (MRQ)Greater than00.678
Operating Margin (MRQ)Greater than00.721
Quick Ratio (MRQ)Greater than125.418
Current Ratio (MRQ)Greater than14.292
Debt to Asset Ratio (MRQ)Less than10.565
Debt to Equity Ratio (MRQ)Less than11.301
Return on Equity (MRQ)Greater than0.150.538
Return on Assets (MRQ)Greater than0.050.234
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Arrowhead Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.124
Ma 20Greater thanMa 5016.126
Ma 50Greater thanMa 10015.290
Ma 100Greater thanMa 20015.375
OpenGreater thanClose16.910
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Fundamental data was last updated by Penke on 2025-06-18 23:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arrowhead Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 67.8% means that $0.68 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 67.8%. The company is making a huge profit. +2
  • The TTM is -0.4%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ67.8%TTM-0.4%+68.1%
TTM-0.4%YOY-1,268.4%+1,268.0%
TTM-0.4%5Y-344.7%+344.4%
5Y-344.7%10Y-7,337.0%+6,992.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ67.8%-91.7%+159.5%
TTM-0.4%-139.0%+138.6%
YOY-1,268.4%-194.4%-1,074.0%
3Y-466.7%-248.5%-218.2%
5Y-344.7%-343.3%-1.4%
10Y-7,337.0%-488.9%-6,848.1%
4.3.1.2. Return on Assets

Shows how efficient Arrowhead Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • 23.4% Return on Assets means that Arrowhead Pharmaceuticals Inc generated $0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 23.4%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -7.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ23.4%TTM-7.0%+30.4%
TTM-7.0%YOY-15.4%+8.4%
TTM-7.0%5Y-7.3%+0.3%
5Y-7.3%10Y-7.9%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.4%-11.6%+35.0%
TTM-7.0%-11.7%+4.7%
YOY-15.4%-11.4%-4.0%
3Y-9.2%-11.9%+2.7%
5Y-7.3%-12.1%+4.8%
10Y-7.9%-13.8%+5.9%
4.3.1.3. Return on Equity

Shows how efficient Arrowhead Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • 53.8% Return on Equity means Arrowhead Pharmaceuticals Inc generated $0.54 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 53.8%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is -104.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ53.8%TTM-104.7%+158.6%
TTM-104.7%YOY-44.3%-60.4%
TTM-104.7%5Y-37.3%-67.4%
5Y-37.3%10Y-23.8%-13.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ53.8%-13.5%+67.3%
TTM-104.7%-15.0%-89.7%
YOY-44.3%-14.5%-29.8%
3Y-57.8%-16.9%-40.9%
5Y-37.3%-17.9%-19.4%
10Y-23.8%-19.9%-3.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arrowhead Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arrowhead Pharmaceuticals Inc is operating .

  • Measures how much profit Arrowhead Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 72.1% means the company generated $0.72  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 72.1%. The company is operating very efficient. +2
  • The TTM is 2.7%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ72.1%TTM2.7%+69.4%
TTM2.7%YOY-1,254.9%+1,257.6%
TTM2.7%5Y-344.1%+346.7%
5Y-344.1%10Y-7,558.0%+7,213.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ72.1%-229.2%+301.3%
TTM2.7%-249.7%+252.4%
YOY-1,254.9%-208.4%-1,046.5%
3Y-460.6%-221.7%-238.9%
5Y-344.1%-344.1%+0.0%
10Y-7,558.0%-470.4%-7,087.6%
4.3.2.2. Operating Ratio

Measures how efficient Arrowhead Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.30 means that the operating costs are $0.30 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.298. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.244. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.298TTM0.244+0.054
TTM0.244YOY14.080-13.836
TTM0.2445Y4.422-4.178
5Y4.42210Y144.322-139.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2982.108-1.810
TTM0.2442.680-2.436
YOY14.0803.080+11.000
3Y5.5643.621+1.943
5Y4.4224.734-0.312
10Y144.3226.546+137.776
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arrowhead Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.29 means the company has $4.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 4.292. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.443. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.292TTM5.443-1.151
TTM5.443YOY5.679-0.236
TTM5.4435Y5.480-0.037
5Y5.48010Y5.288+0.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2923.659+0.633
TTM5.4433.834+1.609
YOY5.6794.141+1.538
3Y5.5924.661+0.931
5Y5.4805.756-0.276
10Y5.2886.151-0.863
4.4.3.2. Quick Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 25.42 means the company can pay off $25.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 25.418. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.296. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.418TTM14.296+11.122
TTM14.296YOY9.520+4.776
TTM14.2965Y9.687+4.608
5Y9.68710Y7.992+1.695
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.4182.799+22.619
TTM14.2963.143+11.153
YOY9.5203.794+5.726
3Y11.0314.307+6.724
5Y9.6875.707+3.980
10Y7.9926.457+1.535
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arrowhead Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arrowhead Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arrowhead Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57 means that Arrowhead Pharmaceuticals Inc assets are financed with 56.5% credit (debt) and the remaining percentage (100% - 56.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.565. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.740. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.565TTM0.740-0.175
TTM0.740YOY0.587+0.152
TTM0.7405Y0.495+0.245
5Y0.49510Y0.363+0.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5650.324+0.241
TTM0.7400.347+0.393
YOY0.5870.329+0.258
3Y0.6300.340+0.290
5Y0.4950.349+0.146
10Y0.3630.379-0.016
4.5.4.2. Debt to Equity Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 130.1% means that company has $1.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 1.301. The company is able to pay all its debts with equity. +1
  • The TTM is 6.569. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ1.301TTM6.569-5.267
TTM6.569YOY1.667+4.901
TTM6.5695Y2.255+4.314
5Y2.25510Y1.290+0.964
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3010.379+0.922
TTM6.5690.435+6.134
YOY1.6670.412+1.255
3Y3.4460.446+3.000
5Y2.2550.460+1.795
10Y1.2900.509+0.781
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arrowhead Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of 1.20 means the investor is paying $1.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is 1.576. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.196. Based on the earnings, the company is cheap. +2
  • The TTM is -2.932. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.576MRQ1.196+0.380
MRQ1.196TTM-2.932+4.128
TTM-2.932YOY-9.062+6.130
TTM-2.9325Y-28.909+25.977
5Y-28.90910Y-36.937+8.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.576-2.282+3.858
MRQ1.196-2.062+3.258
TTM-2.932-2.541-0.391
YOY-9.062-3.722-5.340
3Y-7.884-3.754-4.130
5Y-28.909-6.100-22.809
10Y-36.937-6.653-30.284
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is 1.275. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.967. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -3.576. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.275MRQ0.967+0.307
MRQ0.967TTM-3.576+4.543
TTM-3.576YOY-10.492+6.916
TTM-3.5765Y-23.994+20.418
5Y-23.99410Y-17.035-6.960
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.275-3.101+4.376
MRQ0.967-2.689+3.656
TTM-3.576-3.594+0.018
YOY-10.492-4.363-6.129
3Y-9.179-5.065-4.114
5Y-23.994-8.478-15.516
10Y-17.035-9.273-7.762
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arrowhead Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.57 means the investor is paying $2.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is 3.389. Based on the equity, the company is fair priced.
  • The MRQ is 2.571. Based on the equity, the company is underpriced. +1
  • The TTM is 18.365. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD3.389MRQ2.571+0.817
MRQ2.571TTM18.365-15.794
TTM18.365YOY14.528+3.837
TTM18.3655Y18.066+0.299
5Y18.06610Y14.371+3.695
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3891.932+1.457
MRQ2.5711.848+0.723
TTM18.3652.119+16.246
YOY14.5282.469+12.059
3Y17.2152.526+14.689
5Y18.0663.667+14.399
10Y14.3714.351+10.020
4.6.2. Total Gains per Share

2.4. Latest News of Arrowhead Pharmaceuticals Inc

Does Arrowhead Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Arrowhead Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-24
22:22
Wave Life Sciences' SWOT analysis: RNA editing stock faces fierce competitionRead
2025-06-17
08:45
Sarepta Therapeutics' SWOT analysis: gene therapy pioneer faces safety hurdlesRead
2025-06-14
19:12
Sarepta Therapeutics' SWOT analysis: gene therapy pioneer's stock faces safety hurdlesRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arrowhead Pharmaceuticals Inc.

4.8.1. Institutions holding Arrowhead Pharmaceuticals Inc

Institutions are holding 77.218% of the shares of Arrowhead Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc14.42870.005319926154374815423.1682
2025-03-31Vanguard Group Inc9.56010.0031320256210182738.3573
2025-03-31venBio Select Advisor LLC8.04572.20951111111100
2025-03-31State Street Corp5.06820.0037699924998302216.3395
2025-03-31Slate Path Capital LP3.78851.2038523200000
2025-03-31UBS Asset Mgmt Americas Inc3.46490.015647850622774933138.0475
2025-03-31FMR Inc2.40050.00273315082-1786001-35.0122
2025-03-31Geode Capital Management, LLC2.13640.0032950312-4635-0.1569
2025-03-31Siren, L.L.C.1.93331.91872669880-231801-7.9885
2025-03-31T. Rowe Price Investment Management,Inc.1.83130.02132528982216860.8649
2024-12-31NORGES BANK1.48760.0051205436446904429.5867
2025-03-31Morgan Stanley - Brokerage Accounts1.33850.0017184853631212420.3151
2025-03-31Goldman Sachs Group Inc1.26120.0036174166644745634.5737
2024-12-31UBS Group AG0.94520.00451305329863818195.6504
2025-03-31Northern Trust Corp0.87680.00231210813-273606-18.4319
2025-03-31Aberdeen Group PLC0.77680.02671072827622752138.3663
2025-03-31Charles Schwab Investment Management Inc0.74970.00251035290175701.7264
2025-03-31Citadel Advisors Llc0.71470.0024986951618953168.1947
2025-03-31Two Sigma Investments LLC0.60480.0227835174408015.1363
2025-03-31Western Financial Corp/CA0.59396.071582023900
Total 62.006811.529685631583+9642543+11.3%

4.9.2. Funds holding Arrowhead Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31iShares Core S&P Small-Cap ETF5.4840.1586757346300
2025-04-30Vanguard Total Stock Mkt Idx Inv2.47490.00283417813167160.4915
2025-05-31iShares Russell 2000 ETF2.17520.0784300402800
2025-04-30Vanguard Small Cap Index1.9480.02662690130185140.693
2025-05-31SPDR® S&P Biotech ETF1.60640.75982218459131180.5948
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.40890.0265194565926800.1379
2025-04-30Vanguard Small Cap Growth Index Inv1.08180.06211493984-1130-0.0756
2025-04-30Fidelity Growth Compy Commingled Pl S1.03330.0249142698300
2025-03-31Fidelity Small Cap Index0.86250.0628119113057050.4813
2025-04-30UBS Lux Dgtl Hlth Eq Fd seeding P acc0.82782.14261143187-56813-4.7344
2025-05-30SPDR® Portfolio S&P 600™ Sm Cap ETF0.77340.1581106809500
2025-05-31iShares Russell 2000 Growth ETF0.74720.1501103182600
2025-04-30Fidelity Growth Company Fund0.720.023599432500
2025-04-30Vanguard Tax-Managed Small Cap Adm0.62740.148986645100
2025-03-31T. Rowe Price US Small-Cap Core Equity0.54690.1242755302-729-0.0964
2025-03-31T. Rowe Price Small-Cap Stock0.54690.1242755302-163-0.0216
2025-05-31iShares S&P Small-Cap 600 Value ETF0.54470.20175223800
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.50140.02769248273001.0654
2025-04-30Fidelity Extended Market Index0.50130.0267692287-5605-0.8031
2025-05-31iShares Biotechnology ETF0.44910.199662015100
Total 24.86114.528434333295-4070.0%

5.3. Insider Transactions

Insiders are holding 13.018% of the shares of Arrowhead Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-11Christopher Richard AnzaloneSELL5080011.49
2025-04-09Christopher Richard AnzaloneSELL4032210.07
2025-03-13Christopher Richard AnzaloneSELL5142515.07
2025-03-04Christopher Richard AnzaloneSELL13333317.02
2025-01-23Adeoye Y OlukotunSELL95921
2025-01-06James C HamiltonSELL3272919.82
2025-01-06Kenneth Allen MyszkowskiSELL2716719.83
2025-01-06Patrick O'brienSELL2918419.82
2025-01-02Christopher Richard AnzaloneSELL1152019.05
2024-12-27Adeoye Y OlukotunSELL285020
2024-12-23Christopher Richard AnzaloneSELL1256319.59
2024-12-18Christopher Richard AnzaloneSELL2671221.24
2024-12-16William D WaddillSELL374821.9
2024-07-02Tracie OliverSELL939425.28
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Debt  272,151112,574384,72523,142407,86763,514471,381-657,090-185,709
Income before Tax  -126,996-46,981-173,9771,179-172,798-2,317-175,115544,731369,616
Net Income  -125,300-45,493-170,793257-170,536-2,549-173,085540,948367,863
EBIT  -119,752-49,131-168,88310,732-158,1514,682-153,469544,724391,255
EBITDA  -115,227-48,874-164,10110,975-153,1264,892-148,234553,596405,362
Operating Income  -126,191-49,950-176,14113,938-162,203791-161,412542,614381,202
Net Income from Continuing Operations  -126,996-46,981-173,977633-173,344-1,874-175,218543,081367,863



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,573,498
Total Liabilities889,273
Total Stockholder Equity683,321
 As reported
Total Liabilities 889,273
Total Stockholder Equity+ 683,321
Total Assets = 1,573,498

Assets

Total Assets1,573,498
Total Current Assets185,709
Long-term Assets438,278
Total Current Assets
Cash And Cash Equivalents 185,709
Short-term Investments 911,700
Net Receivables 2,365
Total Current Assets  (as reported)185,709
Total Current Assets  (calculated)1,099,774
+/- 914,065
Long-term Assets
Property Plant Equipment 429,255
Intangible Assets 7,711
Long-term Assets Other 1,312
Long-term Assets  (as reported)438,278
Long-term Assets  (calculated)438,278
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities43,268
Long-term Liabilities846,005
Total Stockholder Equity683,321
Total Current Liabilities
Short Long Term Debt 65,000
Accounts payable 9,980
Other Current Liabilities 448
Total Current Liabilities  (as reported)43,268
Total Current Liabilities  (calculated)75,428
+/- 32,160
Long-term Liabilities
Long term Debt 208,927
Capital Lease Obligations Min Short Term Debt114,311
Long-term Liabilities  (as reported)846,005
Long-term Liabilities  (calculated)323,238
+/- 522,767
Total Stockholder Equity
Other Stockholders Equity 683,321
Total Stockholder Equity (as reported)683,321
Total Stockholder Equity (calculated)683,321
+/-0
Other
Capital Stock230
Cash and Short Term Investments 185,709
Common Stock Shares Outstanding 134,484
Current Deferred Revenue43,268
Liabilities and Stockholders Equity 1,573,498
Net Debt -185,709
Net Invested Capital 957,248
Net Working Capital 914,679
Property Plant and Equipment Gross 497,685



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-31
> Total Assets 
100
100
100
0
100
100
100
71
69
67
65
62
58
58
46
49
50
105
64
48
43
46
1,516
2,128
11,509
12,148
11,916
10,022
14,558
30,707
29,041
25,880
45,085
40,583
34,526
34,394
26,905
36,716
29,853
30,664
24,822
19,126
17,255
15,390
10,168
8,199
7,702
9,129
7,758
14,596
12,355
15,190
15,237
13,290
15,889
23,062
20,081
16,488
16,528
15,231
12,419
41,488
37,330
92,692
202,641
196,623
182,817
162,137
162,378
145,190
132,268
111,381
94,607
85,533
128,177
144,258
126,872
115,082
104,022
88,220
126,999
112,903
111,610
340,947
333,940
336,828
349,845
587,602
561,076
555,728
522,504
499,251
756,795
734,927
710,148
638,539
703,575
751,782
691,939
891,489
891,308
795,856
765,552
626,286
955,150
883,759
1,139,802
1,013,694
1,573,498
1,573,4981,013,6941,139,802883,759955,150626,286765,552795,856891,308891,489691,939751,782703,575638,539710,148734,927756,795499,251522,504555,728561,076587,602349,845336,828333,940340,947111,610112,903126,99988,220104,022115,082126,872144,258128,17785,53394,607111,381132,268145,190162,378162,137182,817196,623202,64192,69237,33041,48812,41915,23116,52816,48820,08123,06215,88913,29015,23715,19012,35514,5967,7589,1297,7028,19910,16815,39017,25519,12624,82230,66429,85336,71626,90534,39434,52640,58345,08525,88029,04130,70714,55810,02211,91612,14811,5092,1281,51646434864105504946585862656769711001001000100100100
   > Total Current Assets 
0
0
0
0
0
0
0
16
17
16
16
15
58
58
46
48
48
70
32
18
15
20
1,514
2,126
11,499
10,937
9,497
7,313
9,702
25,665
22,814
19,519
36,113
31,342
28,776
28,807
22,494
32,106
25,305
26,208
20,547
14,541
10,561
9,021
4,178
2,755
2,484
4,148
2,990
10,126
8,132
11,041
8,581
7,049
9,861
9,174
8,818
5,903
6,567
6,064
3,740
34,411
28,844
76,412
161,923
163,423
154,801
132,165
120,147
114,688
102,871
82,284
66,143
49,601
90,503
106,230
89,690
77,902
67,903
53,107
92,660
61,870
78,769
248,951
234,970
244,539
265,247
507,614
314,474
315,233
322,370
323,716
586,757
525,955
384,597
338,278
417,630
432,388
376,396
501,831
574,810
470,165
419,521
237,899
541,650
450,062
695,471
570,536
185,709
185,709570,536695,471450,062541,650237,899419,521470,165574,810501,831376,396432,388417,630338,278384,597525,955586,757323,716322,370315,233314,474507,614265,247244,539234,970248,95178,76961,87092,66053,10767,90377,90289,690106,23090,50349,60166,14382,284102,871114,688120,147132,165154,801163,423161,92376,41228,84434,4113,7406,0646,5675,9038,8189,1749,8617,0498,58111,0418,13210,1262,9904,1482,4842,7554,1789,02110,56114,54120,54726,20825,30532,10622,49428,80728,77631,34236,11319,51922,81425,6659,7027,3139,49710,93711,4992,1261,5142015183270484846585815161617160000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
1
1
2
0
0
1
0
2
3
57
18
4
0
5
1,355
1,429
10,331
9,839
8,553
6,766
9,311
25,118
22,467
19,105
16,585
16,688
28,020
28,267
21,592
3,421
24,120
25,424
19,522
13,823
10,094
7,637
3,557
1,909
2,020
3,810
2,593
8,983
6,847
5,467
4,790
4,316
7,507
6,773
3,595
2,283
3,377
2,931
3,313
29,026
19,114
59,713
142,848
138,350
132,511
103,991
96,447
87,253
81,214
62,165
50,301
43,617
85,366
102,106
61,719
38,383
24,839
11,531
69,805
27,995
30,133
189,773
161,639
188,332
221,804
461,032
256,651
219,323
143,583
139,921
372,377
325,981
184,434
91,587
86,408
139,439
108,005
202,249
134,959
105,334
110,891
58,215
127,704
69,399
102,685
53,889
185,709
185,70953,889102,68569,399127,70458,215110,891105,334134,959202,249108,005139,43986,40891,587184,434325,981372,377139,921143,583219,323256,651461,032221,804188,332161,639189,77330,13327,99569,80511,53124,83938,38361,719102,10685,36643,61750,30162,16581,21487,25396,447103,991132,511138,350142,84859,71319,11429,0263,3132,9313,3772,2833,5956,7737,5074,3164,7905,4676,8478,9832,5933,8102,0201,9093,5577,63710,09413,82319,52225,42424,1203,42121,59228,26728,02016,68816,58519,10522,46725,1189,3116,7668,5539,83910,3311,4291,355504185732010021100000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437
808
711
488
289
151
66
77
77
18,709
13,945
0
0
0
27,373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,253
1,178
635
72
79
109
107
56
0
4,058
9,030
15,913
17,798
23,834
21,653
23,532
19,561
23,281
17,540
14,431
11,160
1,031
0
0
24,910
36,755
40,770
39,169
21,737
32,485
46,400
53,980
56,561
48,567
36,900
40,969
50,959
67,709
171,909
165,406
204,941
190,331
183,355
238,547
315,487
277,057
268,391
299,582
346,046
346,369
292,735
162,064
395,410
367,272
578,276
499,046
911,700
911,700499,046578,276367,272395,410162,064292,735346,369346,046299,582268,391277,057315,487238,547183,355190,331204,941165,406171,90967,70950,95940,96936,90048,56756,56153,98046,40032,48521,73739,16940,77036,75524,910001,03111,16014,43117,54023,28119,56123,53221,65323,83417,79815,9139,0304,05805610710979726351,1782,2530000000000000027,37300013,94518,70977776615128948871180843700000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
1
2
2
1
2
1
0
1
1
0
0
0
0
0
0
0
0
0
38
52
3
38
91
33
37
42
37
74
37
2
388
276
403
495
157
87
1,009
169
396
147
133
172
736
931
5,373
1,268
1,350
1,608
2,028
4,687
3,079
9
115
0
268
75
75
0
0
75
127
0
0
75
0
0
75
75
60
581
937
68
150
16
15
327
3,169
13,422
2,044
661
1,345
1,266
21,693
846
9,002
955
671
10,255
150
1,317
239
1,410
39,568
69,434
1,247
0
0
0
0
0
2,500
2,365
2,3652,500000001,24769,43439,5681,4102391,31715010,2556719559,00284621,6931,2661,3456612,04413,4223,16932715161506893758160757500750012775007575268011593,0794,6872,0281,6081,3501,2685,3739317361721331473961691,0098715749540327638823774374237339138352380000000001101212210000000
       Other Current Assets 
0
0
0
0
0
0
0
1
1
0
1
0
46
45
39
39
39
0
1
1
1
1
159
260
361
348
405
256
202
390
237
377
777
672
681
503
900
924
909
381
530
560
381
375
451
450
316
206
225
406
354
201
271
205
111
301
457
432
618
461
426
1,060
624
690
1,277
1,239
637
4,514
4,138
4,154
4,117
5,687
4,682
4,954
5,061
4,065
2,480
1,827
2,227
2,256
1,102
1,375
1,908
2,029
3,348
5,596
5,881
4,267
5,599
6,508
6,033
9,387
8,484
8,972
6,553
7,994
14,418
15,653
27,493
33,600
24,371
17,215
15,895
17,620
18,536
13,391
14,510
15,101
11,677
11,67715,10114,51013,39118,53617,62015,89517,21524,37133,60027,49315,65314,4187,9946,5538,9728,4849,3876,0336,5085,5994,2675,8815,5963,3482,0291,9081,3751,1022,2562,2271,8272,4804,0655,0614,9544,6825,6874,1174,1544,1384,5146371,2391,2776906241,060426461618432457301111205271201354406225206316450451375381560530381909924900503681672777377237390202256405348361260159111103939394546010110000000
   > Long-term Assets 
100
100
100
0
100
100
100
55
53
50
49
47
0
0
0
0
2
35
31
30
28
26
2
2
10
1,212
2,419
2,708
4,856
5,042
6,227
6,361
8,972
9,241
5,750
5,587
4,410
4,611
4,548
4,456
4,275
4,585
6,694
6,369
5,990
5,444
5,219
4,981
4,768
4,470
4,223
4,149
6,655
6,241
6,027
13,888
11,263
10,585
9,960
9,167
8,679
7,077
8,486
16,281
40,718
33,200
28,016
29,972
42,232
30,503
29,397
29,097
28,464
35,932
37,674
38,028
37,182
37,179
36,119
35,114
34,338
51,033
32,841
91,997
98,970
92,290
84,599
79,987
246,602
240,495
200,133
175,535
170,038
208,972
325,551
300,261
285,945
319,394
315,543
389,658
316,498
325,691
346,031
388,387
413,500
433,697
444,331
443,158
438,278
438,278443,158444,331433,697413,500388,387346,031325,691316,498389,658315,543319,394285,945300,261325,551208,972170,038175,535200,133240,495246,60279,98784,59992,29098,97091,99732,84151,03334,33835,11436,11937,17937,18238,02837,67435,93228,46429,09729,39730,50342,23229,97228,01633,20040,71816,2818,4867,0778,6799,1679,96010,58511,26313,8886,0276,2416,6554,1494,2234,4704,7684,9815,2195,4445,9906,3696,6944,5854,2754,4564,5484,6114,4105,5875,7509,2418,9726,3616,2275,0424,8562,7082,4191,212102226283031352000047495053551001001000100100100
       Property Plant Equipment 
100
100
100
0
0
0
100
55
53
50
49
47
0
0
0
0
2
35
31
30
28
26
2
2
10
702
882
1,171
1,134
1,236
1,078
1,026
998
1,078
1,271
1,260
1,167
1,429
1,439
1,426
1,420
1,260
1,245
1,094
904
617
527
432
338
256
141
98
32
30
25
6,927
6,745
5,366
4,896
4,427
4,013
3,793
3,513
3,186
3,290
3,674
3,873
4,124
4,127
4,109
4,527
4,666
4,382
12,275
15,387
16,166
15,715
16,135
15,513
14,932
14,582
14,029
13,935
13,921
13,378
17,075
23,215
36,876
39,626
46,912
47,018
49,477
57,770
66,236
66,021
69,178
71,267
140,812
168,588
188,969
226,342
272,036
335,559
378,318
403,878
420,250
431,287
431,938
429,255
429,255431,938431,287420,250403,878378,318335,559272,036226,342188,969168,588140,81271,26769,17866,02166,23657,77049,47747,01846,91239,62636,87623,21517,07513,37813,92113,93514,02914,58214,93215,51316,13515,71516,16615,38712,2754,3824,6664,5274,1094,1274,1243,8733,6743,2903,1863,5133,7934,0134,4274,8965,3666,7456,927253032981412563384325276179041,0941,2451,2601,4201,4261,4391,4291,1671,2601,2711,0789981,0261,0781,2361,1341,17188270210222628303135200004749505355100000100100100
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
446
399
1,443
2,596
3,704
1,762
1,762,150
4,467
4,507
963
963
3,147
3,043
2,939
2,835
2,731
2,628
2,750
2,642
2,541
2,441
2,362
2,284
2,205
2,126
2,047
1,968
1,852
1,792
1,731
2,750
2,675
4,685
4,785
4,710
4,636
3,254
3,241
3,227
3,213
3,200
1,013
1,000
25,702
25,263
24,824
24,385
23,960
23,535
22,165
-21,718,021
21,315
-20,868,656
20,464
-20,019,293
19,614
-19,169,928
18,764
-18,320,564
17,914
17,489
17,064
-16,621,835
16,213
-15,772,470
15,363
14,938
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000014,93815,363-15,772,47016,213-16,621,83517,06417,48917,914-18,320,56418,764-19,169,92819,614-20,019,29320,464-20,868,65621,315-21,718,02122,16523,53523,96024,38524,82425,26325,7021,0001,0133,2003,2133,2273,2413,2544,6364,7104,7854,6852,6752,7501,7311,7921,8521,9682,0472,1262,2052,2842,3622,4412,5412,6422,7502,6282,7312,8352,9393,0433,1479639634,5074,4671,762,1501,7623,7042,5961,4433994460000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,048
26,285
23,088
17,806
12,361
1,085
0
0
0
0
0
0
0
0
0
0
0
17,673
0
59,595
67,536
57,555
44,176
26,329
190,618
177,530
137,487
110,855
97,490
128,376
245,595
217,572
201,590
165,920
105,872
115,774
78,834
42,758
0
0
0
0
0
0
0
000000042,75878,834115,774105,872165,920201,590217,572245,595128,37697,490110,855137,487177,530190,61826,32944,17657,55567,53659,595017,673000000000001,08512,36117,80623,08826,28534,0480000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
446
1,461
1,443
3,622
3,704
5,038
5,171
3,323
3,491
3,354
3,250
3,147
3,043
2,939
2,835
2,731
2,628
2,750
2,642
2,541
2,441
2,362
2,284
2,205
2,126
2,047
1,968
1,852
1,792
1,731
2,750
2,675
4,685
4,785
4,710
4,636
3,254
3,241
3,227
3,213
3,200
1,013
1,000
25,702
25,263
24,824
24,385
23,960
23,535
22,165
21,739,761
21,315
20,889,546
20,464
20,039,332
19,614
19,189,117
18,764
18,338,903
17,914
17,489
17,064
16,638,473
16,213
15,788,258
15,363
14,938
14,513
14,088
13,663
13,238
12,813
12,387
11,962
11,537
11,112
10,687
10,262
9,837
9,412
8,987
8,562
8,137
7,711
7,7118,1378,5628,9879,4129,83710,26210,68711,11211,53711,96212,38712,81313,23813,66314,08814,51314,93815,36315,788,25816,21316,638,47317,06417,48917,91418,338,90318,76419,189,11719,61420,039,33220,46420,889,54621,31521,739,76122,16523,53523,96024,38524,82425,26325,7021,0001,0133,2003,2133,2273,2413,2544,6364,7104,7854,6852,6752,7501,7311,7921,8521,9682,0472,1262,2052,2842,3622,4412,5412,6422,7502,6282,7312,8352,9393,0433,1473,2503,3543,4913,3235,1715,0383,7043,6221,4431,4614460000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
509
1,537
1,538
3,722
3,806
5,149
5,335
7,974
8,163
4,479
4,327
3,244
3,181
3,109
3,030
2,855
3,325
5,449
5,275
5,086
4,827
4,691
4,549
4,430
4,214
4,082
4,051
6,624
6,211
6,003
6,961
4,518
5,219
5,065
4,740
4,666
3,284
4,972
13,094
37,428
29,526
24,143
25,848
38,104
26,394
24,870
24,431
24,082
23,657
22,287
21,862
21,467
21,045
20,606
20,181
142
142
142
142
142
171
144
144
144
265
68,870
40,855
265
272
96,764
273
275
169,366
209,671
210
210
210
210
0
0
0
0
0
1,387,789
1,387,78900000210210210210209,671169,36627527396,76427226540,85568,87026514414414417114214214214214220,18120,60621,04521,46721,86222,28723,65724,08224,43124,87026,39438,10425,84824,14329,52637,42813,0944,9723,2844,6664,7405,0655,2194,5186,9616,0036,2116,6244,0514,0824,2144,4304,5494,6914,8275,0865,2755,4493,3252,8553,0303,1093,1813,2444,3274,4798,1637,9745,3355,1493,8063,7221,5381,5375090000000000000000000000000
> Total Liabilities 
2,700
2,700
2,900
0
2,700
1,000
1,100
1,124
1,176
1,231
1,194
1,221
1,269
1,302
1,351
1,416
1,428
1,571
1,614
1,644
1,744
1,800
96
20
38
373
690
352
579
993
1,024
1,457
2,589
1,729
2,920
1,015
1,146
2,940
3,396
2,783
2,794
3,055
4,953
10,390
9,762
4,485
2,844
2,580
2,280
5,140
4,276
7,902
3,015
2,721
3,324
7,313
8,514
8,039
7,719
7,627
8,659
8,183
11,595
11,782
13,104
10,815
16,832
16,427
18,182
14,446
22,646
19,013
20,681
26,108
33,152
47,050
33,535
25,539
23,155
18,021
13,284
11,144
16,369
169,447
133,300
111,158
105,809
88,073
67,512
63,143
60,725
44,779
311,246
298,037
301,326
265,979
251,309
277,605
585,979
495,117
426,202
413,871
478,390
452,572
459,745
544,785
948,739
957,619
889,273
889,273957,619948,739544,785459,745452,572478,390413,871426,202495,117585,979277,605251,309265,979301,326298,037311,24644,77960,72563,14367,51288,073105,809111,158133,300169,44716,36911,14413,28418,02123,15525,53933,53547,05033,15226,10820,68119,01322,64614,44618,18216,42716,83210,81513,10411,78211,5958,1838,6597,6277,7198,0398,5147,3133,3242,7213,0157,9024,2765,1402,2802,5802,8444,4859,76210,3904,9533,0552,7942,7833,3962,9401,1461,0152,9201,7292,5891,4571,0249935793526903733820961,8001,7441,6441,6141,5711,4281,4161,3511,3021,2691,2211,1941,2311,1761,1241,1001,0002,70002,9002,7002,700
   > Total Current Liabilities 
2,700
2,600
2,800
0
2,600
1,000
1,000
1,085
1,137
1,190
1,155
1,184
1,233
1,267
1,318
1,384
1,397
1,542
1,587
1,618
1,716
1,773
96
20
38
373
690
352
579
993
1,024
1,457
2,589
1,729
2,920
1,015
1,146
2,940
2,896
2,283
2,294
2,555
3,726
4,860
4,449
3,410
2,344
2,580
2,280
5,140
4,276
7,902
2,495
2,160
2,582
5,060
6,376
5,815
5,328
6,078
7,164
6,678
8,725
9,018
10,483
8,250
11,847
11,498
13,210
9,532
15,901
12,328
14,058
14,840
25,644
36,998
27,552
20,320
18,701
13,716
9,124
7,127
12,365
134,612
101,812
87,087
97,071
73,695
53,333
42,783
40,681
25,094
167,188
195,434
146,536
137,032
138,857
128,212
74,099
66,281
87,151
70,227
105,456
63,723
65,175
96,714
103,168
93,758
43,268
43,26893,758103,16896,71465,17563,723105,45670,22787,15166,28174,099128,212138,857137,032146,536195,434167,18825,09440,68142,78353,33373,69597,07187,087101,812134,61212,3657,1279,12413,71618,70120,32027,55236,99825,64414,84014,05812,32815,9019,53213,21011,49811,8478,25010,4839,0188,7256,6787,1646,0785,3285,8156,3765,0602,5822,1602,4957,9024,2765,1402,2802,5802,3443,4104,4494,8603,7262,5552,2942,2832,8962,9401,1461,0152,9201,7292,5891,4571,0249935793526903733820961,7731,7161,6181,5871,5421,3971,3841,3181,2671,2331,1841,1551,1901,1371,0851,0001,0002,60002,8002,6002,700
       Short-term Debt 
0
0
0
0
0
0
0
525
525
523
524
525
526
526
526
526
506
606
606
606
603
602
0
0
0
0
0
0
0
0
0
632
633
0
0
0
0
0
1,041
892
0
0
810
827
843
860
727
1,014
796
575
500
500
0
958
945
210
212
213
315
1,152
1,098
1,145
1,193
1,271
1,262
263
264
214
216
217
218
218
219
361
194
198
201
205
209
212
216
220
224
224
0
0
11,635
461
688
1,012
1,095
2,366
2,544
2,580
4,500
5,652
5,820
5,766
5,552
5,328
2,711
5,646
21,126
6,842
5,285
12,106
6,342
1,625
0
01,6256,34212,1065,2856,84221,1265,6462,7115,3285,5525,7665,8205,6524,5002,5802,5442,3661,0951,01268846111,635002242242202162122092052011981943612192182182172162142642631,2621,2711,1931,1451,0981,15231521321221094595805005005757961,014727860843827810008921,041000006336320000000006026036066066065065265265265265255245235255250000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
758
0
0
1,430
194
317
347
2,583
209
212
216
220
224
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,625
65,000
65,0001,6250000000000000000000000002242202162122092,5833473171941,4300075800050000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,100
1,100
1,400
0
1,000
200
200
187
209
229
161
156
168
167
180
208
243
247
259
273
299
317
93
15
32
297
541
284
445
343
472
491
1,715
209
847
392
490
1,454
1,349
881
1,161
1,084
1,342
1,911
2,002
1,399
1,013
892
884
1,033
682
2,424
236
501
577
714
801
994
878
810
872
1,062
1,200
589
2,512
2,158
2,579
5,995
4,936
4,862
5,032
5,289
7,542
5,945
12,233
3,698
2,598
3,233
4,077
5,707
1,810
2,166
2,806
3,937
4,062
4,630
7,650
12,202
13,418
4,074
6,829
4,827
5,299
10,037
9,457
4,068
10,603
5,894
2,868
796
9,556
7,874
35,866
4,460
8,521
26,550
11,388
14,457
9,980
9,98014,45711,38826,5508,5214,46035,8667,8749,5567962,8685,89410,6034,0689,45710,0375,2994,8276,8294,07413,41812,2027,6504,6304,0623,9372,8062,1661,8105,7074,0773,2332,5983,69812,2335,9457,5425,2895,0324,8624,9365,9952,5792,1582,5125891,2001,0628728108789948017145775012362,4246821,0338848921,0131,3992,0021,9111,3421,0841,1618811,3491,4544903928472091,7154914723434452845412973215933172992732592472432081801671681561612292091872002001,00001,4001,1001,100
       Other Current Liabilities 
1,600
1,500
1,400
0
1,600
800
800
373
403
438
471
503
539
574
612
650
648
689
722
738
814
853
3
5
7
76
149
68
135
506
446
897
843
1,519
2,074
624
656
1,108
1,449
1,364
1,133
1,472
1,574
2,122
1,603
1,151
604
674
599
3,533
3,095
4,978
2,259
1,658
2,005
4,035
5,293
4,536
4,098
4,007
5,128
4,399
6,332
7,158
6,709
5,757
9,004
5,289
8,058
4,454
10,651
6,821
6,296
8,534
13,217
7,518
3,583
3,598
9,146
5,922
5,532
3,798
9,334
5,750
6,860
6,775
11,651
6,998
6,053
11,423
32,757
11,157
14,466
60,118
33,275
34,352
45,365
61,880
100,411
95,114
45,045
39,802
47,598
52,421
51,369
58,058
85,438
77,676
448
44877,67685,43858,05851,36952,42147,59839,80245,04595,114100,41161,88045,36534,35233,27560,11814,46611,15732,75711,4236,0536,99811,6516,7756,8605,7509,3343,7985,5325,9229,1463,5983,5837,51813,2178,5346,2966,82110,6514,4548,0585,2899,0045,7576,7097,1586,3324,3995,1284,0074,0984,5365,2934,0352,0051,6582,2594,9783,0953,5335996746041,1511,6032,1221,5741,4721,1331,3641,4491,1086566242,0741,51984389744650613568149767538538147387226896486506125745395034714384033738008001,60001,4001,5001,600
   > Long-term Liabilities 
0
100
100
0
100
0
100
40
39
41
39
38
36
35
33
32
31
29
28
26
28
28
0
0
0
928
1,778
0
1,536
0
1,889
1,092,753
0
1,229,462
934,438
3,216,137
0
600,038
500
500
500
500
1,227
5,530
5,313
1,075
500
500
0
0
0
0
520
561
742
2,253
2,139
2,224
2,391
1,549
1,495
1,505
2,870
2,764
2,621
2,565
4,984
4,929
4,972
4,913
6,746
6,685
6,623
11,268
7,508
10,052
5,984
5,220
4,454
4,305
4,160
4,017
4,004
34,836
31,488
24,071
8,739
14,378
14,179
20,360
20,043
19,685
144,058
102,603
154,790
128,947
112,452
149,393
511,880
428,836
339,051
343,644
372,934
388,849
394,570
448,071
845,571
863,861
846,005
846,005863,861845,571448,071394,570388,849372,934343,644339,051428,836511,880149,393112,452128,947154,790102,603144,05819,68520,04320,36014,17914,3788,73924,07131,48834,8364,0044,0174,1604,3054,4545,2205,98410,0527,50811,2686,6236,6856,7464,9134,9724,9294,9842,5652,6212,7642,8701,5051,4951,5492,3912,2242,1392,25374256152000005005001,0755,3135,5301,227500500500500600,03803,216,137934,4381,229,46201,092,7531,88901,53601,778928000282826282931323335363839413940100010001001000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
561
607
2,147
2,139
2,130
2,122
1,278
1,223
1,167
1,111
1,006
866
812
758
705
650
596
541
486
431
2,962
2,533
2,483
2,431
2,379
2,325
2,271
2,215
2,159
2,101
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000002,1012,1592,2152,2712,3252,3792,4312,4832,5332,9624314865415966507057588128661,0061,1111,1671,2231,2782,1222,1302,1392,14760756100000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
500
500
500
500
500
500
0
0
0
0
0
0
0
0
0
136
106
0
93
269
271
272
337
1,759
1,758
1,754
1,753
4,227
4,225
4,322
4,318
6,204
6,199
6,192
8,306
4,976
7,569
3,552
2,841
2,129
2,034
1,945
1,858
1,903
34,836
31,488
24,071
8,739
0
0
0
41,434
0
121,530
79,749
190,271
106,458
89,754
193,317
199,501
293,638
258,981
263,733
0
0
0
0
0
0
0
0000000263,733258,981293,638199,501193,31789,754106,458190,27179,749121,530041,4340008,73924,07131,48834,8361,9031,8581,9452,0342,1292,8413,5527,5694,9768,3066,1926,1996,2044,3184,3224,2254,2271,7531,7541,7581,75933727227126993010613600000000050050050050050050050000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,243
4,775
7,369
3,352
2,641
1,929
1,834
1,745
1,658
1,703
1,664
1,755
1,812
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,8121,7551,6641,7031,6581,7451,8341,9292,6413,3527,3694,7752,2430000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
-2,600
-2,600
-2,800
0
-2,600
-900
-1,000
-1,054
-1,106
-1,164
-1,129
-1,159
-1,211
-1,244
-1,304
-1,368
-1,378
-1,466
-1,551
-1,596
-1,701
-1,754
1,420
2,107
11,471
10,847
9,448
8,223
12,443
28,457
26,127
23,331
41,200
37,625
30,671
30,162
24,477
33,176
26,304
23,771
19,064
13,100
12,303
5,000
406
3,714
4,858
6,671
5,878
10,113
9,046
8,049
12,085
10,626
12,791
16,169
12,236
9,365
10,013
8,975
5,313
34,957
27,499
82,732
191,399
186,363
166,540
146,265
144,752
131,300
110,177
92,924
74,481
59,980
95,579
97,764
93,892
90,097
81,422
70,754
114,270
102,315
95,796
172,055
201,195
226,225
244,591
500,084
494,119
493,140
461,779
454,472
445,549
436,890
408,822
372,560
452,266
453,927
105,960
377,039
446,772
364,830
271,343
160,407
483,794
330,547
185,444
52,589
683,321
683,32152,589185,444330,547483,794160,407271,343364,830446,772377,039105,960453,927452,266372,560408,822436,890445,549454,472461,779493,140494,119500,084244,591226,225201,195172,05595,796102,315114,27070,75481,42290,09793,89297,76495,57959,98074,48192,924110,177131,300144,752146,265166,540186,363191,39982,73227,49934,9575,3138,97510,0139,36512,23616,16912,79110,62612,0858,0499,04610,1135,8786,6714,8583,7144065,00012,30313,10019,06423,77126,30433,17624,47730,16230,67137,62541,20023,33126,12728,45712,4438,2239,44810,84711,4712,1071,420-1,754-1,701-1,596-1,551-1,466-1,378-1,368-1,304-1,244-1,211-1,159-1,129-1,164-1,106-1,054-1,000-900-2,6000-2,800-2,600-2,600
   Common Stock
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
14
14
14
14
15
28
28
28
34
34
34
34
34
39
39
39
39
39
43
43
43
46
56
62
64
71
72
72
72
72
86
105
106
106
108
110
109
124
125
131
144
145
147
147
152
152
152
152
152
153
162
167
167
167
167
167
180
180
181
185
187
188
188
193
194
195
195
195
196
197
197
197
198
198
105,960
106,140
199
199
200
200
217
217
217
218
0
0218217217217200200199199106,140105,96019819819719719719619519519519419318818818718518118018016716716716716716215315215215215215214714714514413112512410911010810610610586727272727164625646434343393939393934343434342828281514141414655555555555555550000000
   Retained Earnings -1,428,163-1,798,608-1,625,523-1,454,987-1,284,194-1,158,894-1,026,030-916,351-813,405-862,080-820,755-735,244-663,198-707,564-644,692-581,318-551,394-524,576-503,844-455,411-441,800-421,965-419,291-430,996-451,332-475,229-487,266-476,505-460,899-446,014-432,815-422,083-416,564-410,521-398,435-376,213-356,792-335,976-316,712-291,969-276,033-247,346-224,771-202,341-190,712-176,769-166,141-152,449-146,370-139,612-134,998-129,684-121,692-116,357-113,872-111,095-109,275-112,181-110,743-108,739-108,368-106,514-104,969-101,345-98,816-93,527-85,496-76,838-69,336-63,641-58,407-50,835-38,357-32,183-28,476-19,697-15,723-12,616-9,217-6,522-3,486-4,129-2,592-1,115-477-301-95-9,816-9,763-9,658-9,613-9,528-9,440-9,430-9,367-9,306-9,273-9,222-9,181-9,216-9,158-9,104-9,000-9,900-9,5000-9,600-9,400-9,400
   Accumulated Other Comprehensive Income 
-100
-100
-100
0
-100
-100
-100
-64
-66
-68
-69
-72
-2
-2
-11
-11
-11
-81
-82
-83
-85
-87
0
0
-1
-528
-194
-334
-263
-690
-728
-3,208
-3,074
-4,971
-1,088
-1,215
-1,345
-1,494
-1,676
-1,857
-2,051
-1,412
-1,596
-1,775
-1,915
-929
-1,025
-1,121
-1,214
-1,296
-1,176
-1,220
-396
-336
-340
-723
-1,072
-1,421
-1,566
-1,941
-2,316
-2,696
-3,081
-3,276
-3,673
-3,933
-4,190
-4,447
-64
-66
-136
-91
60
-31
7
-185
-31
-18
33
24
25
-3
-22
-44
-72
-103
-392
-196
-629
-175
18
198
102
62
-69
-108
-107
-140
-136
-258
-332
-411
-3,222
-1,255
-1,095
-987
4,750
4,137
0
04,1374,750-987-1,095-1,255-3,222-411-332-258-136-140-107-108-696210219818-175-629-196-392-103-72-44-22-3252433-18-31-1857-3160-91-136-66-64-4,447-4,190-3,933-3,673-3,276-3,081-2,696-2,316-1,941-1,566-1,421-1,072-723-340-336-396-1,220-1,176-1,296-1,214-1,121-1,025-929-1,915-1,775-1,596-1,412-2,051-1,857-1,676-1,494-1,345-1,215-1,088-4,971-3,074-3,208-728-690-263-334-194-528-100-87-85-83-82-81-11-11-11-2-2-72-69-68-66-64-100-100-1000-100-100-100
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
121,649
127,476
136,319
136,488
139,943
145,918
149,976
151,573
187,282
193,515
259,369
381,967
388,558
391,165
393,464
420,697
423,183
426,873
428,839
431,061
436,071
493,845
508,303
510,319
512,032
514,037
516,578
574,964
578,642
582,903
647,143
652,412
657,137
664,086
922,051
936,354
948,532
965,410
978,655
996,645
1,017,949
1,053,386
1,080,035
1,115,373
1,189,113
1,219,213
1,239,178
1,260,310
1,281,393
0
0
0
0
0
0
0
00000001,281,3931,260,3101,239,1781,219,2131,189,1131,115,3731,080,0351,053,3861,017,949996,645978,655965,410948,532936,354922,051664,086657,137652,412647,143582,903578,642574,964516,578514,037512,032510,319508,303493,845436,071431,061428,839426,873423,183420,697393,464391,165388,558381,967259,369193,515187,282151,573149,976145,918139,943136,488136,319127,476121,64900000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000-73,926-92,368-109,622-130,744-144,196-145,710-165,985-185,808-189,538-80,910-25,735-33,306-3,761-7,604-8,8090000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
6,900
6,900
6,900
0
7,000
9,100
8,100
8,107
8,110
8,112
8,114
8,126
8,057
8,057
8,066
8,066
8,066
8,136
8,139
8,138
8,140
8,142
1,510
2,403
11,934
11,949
12,221
12,672
16,176
35,641
36,307
39,127
59,962
62,259
59,113
62,312
62,800
83,972
84,673
87,373
88,361
89,899
97,756
98,484
99,179
105,013
109,770
113,124
114,182
118,781
119,717
120,158
121,289
121,985
126,917
132,421
133,823
138,943
144,902
148,476
151,573
187,282
193,515
259,369
381,967
388,558
391,165
393,464
420,697
423,183
426,873
428,839
431,061
436,071
493,845
508,303
510,319
512,032
514,037
516,578
574,964
578,642
582,903
647,143
652,412
657,137
664,086
922,051
936,354
948,532
965,410
978,655
996,645
1,017,949
1,053,386
1,080,035
1,115,373
1,189,113
1,219,213
1,239,178
1,260,310
1,281,393
1,300,395
1,320,356
1,768,866
1,786,304
1,806,000
1,846,842
683,321
683,3211,846,8421,806,0001,786,3041,768,8661,320,3561,300,3951,281,3931,260,3101,239,1781,219,2131,189,1131,115,3731,080,0351,053,3861,017,949996,645978,655965,410948,532936,354922,051664,086657,137652,412647,143582,903578,642574,964516,578514,037512,032510,319508,303493,845436,071431,061428,839426,873423,183420,697393,464391,165388,558381,967259,369193,515187,282151,573148,476144,902138,943133,823132,421126,917121,985121,289120,158119,717118,781114,182113,124109,770105,01399,17998,48497,75689,89988,36187,37384,67383,97262,80062,31259,11362,25959,96239,12736,30735,64116,17612,67212,22111,94911,9342,4031,5108,1428,1408,1388,1398,1368,0668,0668,0668,0578,0578,1268,1148,1128,1108,1078,1009,1007,00006,9006,9006,900



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue355,100
Cost of Revenue-0
Gross Profit355,100355,100
 
Operating Income (+$)
Gross Profit355,100
Operating Expense-604,631
Operating Income-601,080-249,531
 
Operating Expense (+$)
Research Development505,870
Selling General Administrative96,820
Selling And Marketing Expenses1,941
Operating Expense604,631604,631
 
Net Interest Income (+$)
Interest Income22,720
Interest Expense-32,352
Other Finance Cost-0
Net Interest Income-9,632
 
Pretax Income (+$)
Operating Income-601,080
Net Interest Income-9,632
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-612,460-589,700
EBIT - interestExpense = -612,460
-602,260
-567,141
Interest Expense32,352
Earnings Before Interest and Taxes (EBIT)-580,108-580,108
Earnings Before Interest and Taxes (EBITDA)-561,513
 
After tax Income (+$)
Income Before Tax-612,460
Tax Provision--2,767
Net Income From Continuing Ops-609,693-609,693
Net Income-599,493
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses604,631
Total Other Income/Expenses Net-11,3809,632
 

Technical Analysis of Arrowhead Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arrowhead Pharmaceuticals Inc. The general trend of Arrowhead Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arrowhead Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Arrowhead Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arrowhead Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 17.05 < 17.19 < 17.49.

The bearish price targets are: 14.97 > 14.93 > 14.92.

Know someone who trades $ARWR? Share this with them.👇

Arrowhead Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arrowhead Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arrowhead Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arrowhead Pharmaceuticals Inc. The current macd is 0.25823039.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arrowhead Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arrowhead Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arrowhead Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Arrowhead Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartArrowhead Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arrowhead Pharmaceuticals Inc. The current adx is 16.00.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arrowhead Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Arrowhead Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arrowhead Pharmaceuticals Inc. The current sar is 14.97.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Arrowhead Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arrowhead Pharmaceuticals Inc. The current rsi is 60.12. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Arrowhead Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartArrowhead Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arrowhead Pharmaceuticals Inc. The current phase is Overbought in neutral market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arrowhead Pharmaceuticals Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Arrowhead Pharmaceuticals Inc Daily Stochastic Oscillator ChartArrowhead Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arrowhead Pharmaceuticals Inc. The current cci is 106.37.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Arrowhead Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartArrowhead Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arrowhead Pharmaceuticals Inc. The current cmo is 27.20.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arrowhead Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartArrowhead Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arrowhead Pharmaceuticals Inc. The current willr is -17.33333333.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Arrowhead Pharmaceuticals Inc Daily Williams %R ChartArrowhead Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arrowhead Pharmaceuticals Inc. The current atr is 0.80348614.

Arrowhead Pharmaceuticals Inc Daily Average True Range (ATR) ChartArrowhead Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arrowhead Pharmaceuticals Inc. The current obv is -27,596,758.

Arrowhead Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartArrowhead Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arrowhead Pharmaceuticals Inc. The current mfi is 50.56.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Arrowhead Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartArrowhead Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arrowhead Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Arrowhead Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arrowhead Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.124
Ma 20Greater thanMa 5016.126
Ma 50Greater thanMa 10015.290
Ma 100Greater thanMa 20015.375
OpenGreater thanClose16.910
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arrowhead Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Arrowhead Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arrowhead Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arrowhead Pharmaceuticals Inc

I send you an email if I find something interesting about Arrowhead Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Arrowhead Pharmaceuticals Inc.

Receive notifications about Arrowhead Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.